March 4, 2020

To: Advanced Life Support (ALS) Providers
   ALS Medical Directors
   Emergency Department Managers

From: Bryn Mumma, MD, MAS, EMS Agency Medical Director

RE: Advanced Airway Management and Use of Nebulized Medications Associated With COVID-19 Treatment and Transport

Due to recent developments associated with the spread of COVID-19, the safety of airway management and nebulized medications has been brought to the attention of the Emergency Medical Services (EMS) Agency as a concern.

The EMS Agency recognizes that advanced airway management and administration of nebulized medications with patients exhibiting signs and symptoms of Influenza Like Illness (ILI) as now potentially high risk procedures.

Thus, effective immediately, the EMS Agency recommends using Basic Life Support (BLS) airway techniques rather than advanced airway management in patients with lower respiratory symptoms. The EMS agency also advises against nebulized medications in patients with lower respiratory symptoms. Use of albuterol metered dose inhalers (MDIs) with or without a spacer is authorized if MDIs are available to your department or agency.

If you have any questions please contact the EMS Agency.

Sincerely,

Bryn Mumma, MD, MAS,
EMS Agency Medical Director

cc: Ted Selby, EMS Agency Administrator
    Keith Erickson, EMT-P, EMS Coordinator
    Benjamin Gammon, EMT-P, EMS Coordinator